AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM) Files An 8-K Entry into a Material Definitive Agreement

AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement

On September 10, 2018, AXIM Biotechnologies, Inc. (the “Company”) enteredintoa Letter of Intent (“LOI”) with Impression Healthcare Limited (“Impression”), Australia’s largest home dental impression company, for exclusive distribution of all AXIM® Biotech products throughout Australia and New Zealand.

to the LOI, both parties will endeavor to enter into a definitive agreement whereby the parties will co-develop new products, initially for pre-clinical and phase 1 trials (among other clinical trials), including an oral rinse liquid targeted for the treatment of oral mucositis, strep throat, oral infections and gum disease. Pending initial discussions and an internal review of AXIM® Biotech and its product offerings, Impression will collaborate with AXIM® Biotech for the licensing and distribution of its current and future medicinal cannabis products for distribution in Australia and New Zealand.

Item 7.01 Regulation FD Disclosure

On September 13, 2018, the Company issued a press release announcing that it had entered into the agreement. A copy of the press release issued by the Company is attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference solely for purposes of this Item 7.01 disclosure.

Exhibit 99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 – Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release


AXIM BIOTECHNOLOGIES, INC. Exhibit
EX-99.1 2 f8k091318_ex99z1.htm EXHIBIT 99.1 PRESS RELEASE Exhibit 99.1 Press Release   Exhibit 99.1     AXIM® BIOTECHNOLOGIES SIGNS LOI FOR DISTRIBUTION OF PRODUCTS THROUGHOUT AUSTRALIA AND NEW ZEALAND   Leading Cannabinoid Biotech Company Signs Letter of Intent with Leading Australian Healthcare Company for Development of New Products and Assistance with Obtaining Regulatory Approval   NEW YORK – September 13,…
To view the full exhibit click here

About AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM)

AXIM Biotechnologies, Inc., formerly Axim International, Inc., is a biotechnology company. The Company is engaged in developing the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids-based products. It is focused on research, development and production of pharmaceutical, nutriceutical and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. It is engaged in the business of research, development and production of alternative and renewable sources of energy, such as high caloric content fuels produced from industrial hemp and from the byproducts of industrial hemp after completion of the oil extraction/decarboxylation process. It is engaged in the research and development of pharmaceutical delivery systems and active pharmaceutical ingredients (API) for treatment of conditions, such as Parkinson’s disease, Alzheimer’s disease, restless leg syndrome (RLS) and Crohn’s disease.

An ad to help with our costs